Brief: Tenaya Therapeutics Q3 Net Income USD -29.143 Million
08/11/2023 21:05
Nov 08 (Reuters) - Tenaya Therapeutics Q3 basic EPS USD -0.39. * Q3 operating income USD -30.92 million * Q3 operating expenses USD 30.92 million * Q3 pretax profit USD -29.143 million
Recent news on Tenaya Therapeutics
See all newsBrief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401
Tenaya Therapeutics Q1 net loss widens, misses analyst expectations
Brief: Tenaya Therapeutics Q1 Net Income USD -19.272 Million
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027